EPISODE · May 19, 2026 · 12 MIN
Last Week in Biomedicine | May 11–15 | Part 1
from Last Week in Biomedicine · host TrialBreaks
Top 10 significant clinical trial results from last weekPart 1:1. REGENXBIO ($RGNX) — RGX-202 microdystrophin gene therapy for Duchenne muscular dystrophy (Phase 3)2. Alkermes ($ALKS) — LUMRYZ (sodium oxybate once-nightly) for idiopathic hypersomnia (Phase 3)3. Viking Therapeutics ($VKTX) — oral VK2735 (GLP-1/GIP dual agonist) for obesity (Phase 2)4. Inhibrx Biosciences ($INBX) — INBRX-106 (hexavalent OX40 agonist) plus pembrolizumab for first-line PD-L1+ head and neck squamous cell carcinoma (Phase 2)5. United Therapeutics ($UTHR) — Tyvaso (inhaled treprostinil) for idiopathic pulmonary fibrosis (Phase 3)Subscribe for weekly clinical trial breakdowns at TrialBreaks.com#biotech #clinicaltrials #pharma #genetherapy #Duchenne #DMD #GLP1 #obesity #oncology #immunotherapy #headandneckcancer #pulmonology #IPF #cysticfibrosis#womenshealth #prostatecancer #glioblastoma #ovariancancer #sleepmedicine
Embed this episode
NOW PLAYING
Last Week in Biomedicine | May 11–15 | Part 1
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.